{
  "pmcid": "9996687",
  "sha256": "ee8240ea437a1f3ff3999c3bfe8ff96c9063f3364a46fd7b5a4c5f5d71e02c00",
  "timestamp_utc": "2025-11-09T23:03:18.625664+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.966206896551725,
    "reading_ease": 33.65781609195403,
    "word_count": 232
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Embolic Protection Devices in Surgical Aortic Valve Replacement"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 383 patients undergoing SAVR"
      },
      "Participants": {
        "score": 1,
        "evidence": "383 patients undergoing SAVR, with 41% receiving concomitant coronary artery bypass grafting (CABG)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "to assess the efficacy of embolic protection devices"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was 90-day functional status, neurocognitive decline from pre-surgical baseline, and quality of life (QoL)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "383 patients undergoing SAVR"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Stroke was associated with longer hospital stays (HR 0.62; 95% CI 0.42–0.94; p=0.02) and poorer outcomes at 90 days, including higher modified Rankin scores (OR 5.9; 95% CI 1.7–20.1; p=0.01), depression (OR 5.3; 95% CI 1.6–17.3; p=0.006), and neurocognitive decline (OR 7.8; 95% CI 2.3–26.4; p=0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "By day 7, 25 (6.6%) patients experienced stroke, and 103 (28.5%) had delirium."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 15,
    "max_score": 25
  }
}